

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 February 2020 (13.02.2020)



(10) International Publication Number
WO 2020/033630 A1

- (51) **International Patent Classification:**
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/US2019/045632
- (22) **International Filing Date:**
08 August 2019 (08.08.2019)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/716,207 08 August 2018 (08.08.2018) US
- (71) **Applicant:** **DRAGONFLY THERAPEUTICS, INC.**
[US/US]; 35 Gatehouse Drive, Waltham, MA 02451 (US).
- (72) **Inventors:** **BIGELOW, Mitchell**; 6 Emmons Pl., Cambridge, MA 02138 (US). **CHANG, Gregory P.**; 143 Saunders Street, Medford, MA 02155 (US). **CHEUNG, Ann F.**; 25 Morningside Lane, Lincoln, MA 01773 (US). **GRINBERG, Asya**; 37 Follen Road, Lexington, MD 02421 (US). **HANEY, William**; 61 Lincoln Road, Wayland, MA 01778 (US). **WAGTMANN, Nicolai**; 1776 Monument Street, Concord, MA 01742 (US). **LUNDE, Bradley M.**; 7 Lucent Drive, Lebanon, NH 03766 (US). **PRINZ, Bianka**; 7 Lucent Drive, Lebanon, NH 03766 (US).
- (74) **Agent:** **MARTINEK, Sebastian et al.**; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE

FIG. 1A



(57) **Abstract:** Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.

WO 2020/033630 A1